Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Kaufman

Allergy & Immunology Shreveport, LA Medical Doctor

NPI 1164482725 CMS profile 279445

463 Ashley Ridge Blvd, Ste 100, Shreveport, LA 71106

Open in the dashboard

General payments

$678,338

1,392 records reported · program years 2019–2025

Research payments

$2,451

Paid to them · 18 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$107,140 paid to institutions, not to them · program years 2019–2025

Through program year 2025, David Kaufman of Shreveport, LA is reported in the CMS Open Payments database as having received $678,338 across 1,392 general payments and $2,451 in research payments paid to them. Separately, studies naming them as principal investigator received $107,140 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $175,123 315
2024 General $115,074 189
2024 Research $2,451 18
2023 General $123,074 228
2022 General $87,802 210
2021 General $85,252 148
2020 General $25,815 92
2019 General $66,200 210

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Kaufman
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to David Kaufman were reported at $175,123. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year David Kaufman Allergy & Immunology median Middle half National median
2019 $66,200 $594 $163–$1,512 $163
2020 $25,815 $426 $106–$1,233 $114
2021 $85,252 $638 $157–$1,708 $132
2022 $87,802 $790 $205–$1,961 $149
2023 $123,074 $852 $220–$2,147 $160
2024 $115,074 $865 $203–$2,267 $164
2025 $175,123 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $192,421 235 payments
  2. BioCryst US Sales Co., LLC $103,227 131 payments
  3. GlaxoSmithKline, LLC. $100,829 233 payments
  4. Regeneron Healthcare Solutions, Inc. $88,549 156 payments
  5. Blueprint Medicines Corporation $65,664 89 payments
  6. Shire North American Group Inc $32,855 68 payments
  7. Sanofi US Services Inc. $31,535 27 payments
  8. Ionis Pharmaceuticals, Inc. $22,436 23 payments
  9. BioCryst Pharmaceuticals, Inc. $7,789 14 payments
  10. CSL Behring $7,205 17 payments
  11. Other $25,827 399 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $459,521 134 payments
  2. Travel and Lodging $73,688 323 payments
  3. Honoraria $65,369 33 payments
  4. Consulting Fee $51,897 20 payments
  5. Food and Beverage $27,670 878 payments
  6. Education $193 4 payments
Products named General payments · program years 2019–2025
  1. CINRYZE $113,161 172 payments
  2. TAKHZYRO $108,835 125 payments
  3. Orladeyo $104,104 131 payments
  4. NUCALA Immunology $63,762 121 payments
  5. AYVAKIT Oncology / Rare Diseases $56,119 75 payments
  6. DUPIXENT Inflammation And Immunology $54,115 100 payments
  7. NUCALA Respiratory $36,277 52 payments
  8. DUPIXENT Immunology And Inflammation $27,051 50 payments
  9. AYVAKIT Gastroenterology $25,102 24 payments
  10. DAWNZERA $22,436 23 payments
  11. Other $50,961 515 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,451 18 payments

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

313

Median for Allergy/ Immunology: 449

Drug cost

$269,458

Median for Allergy/ Immunology: $169,700

Branded share of claims

42.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 49 $188,985
Tezspire Tezepelumab-Ekko Brand 11 $47,430
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 44 $29,729
Azelastine Hcl Generic 50 $856
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 12 $835
Albuterol Sulfate Hfa Albuterol Sulfate Brand 16 $335
Fluticasone Propionate Generic 30 $266
Ipratropium Bromide Generic 16 $261
Tramadol Hcl Generic 22 $237
Montelukast Sodium Generic 25 $218

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$11,757

Medicare's payments for the services billed

Medicare patients

92

Average age 67

Services billed

1,193

61 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 42%
Diabetes 25%
Ischemic heart disease 24%
Depression 21%
Chronic kidney disease 20%
COPD 15%
Osteoporosis 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TAKHZYRO
$56,391 — —
DUPIXENT
$19,698 49 —
Orladeyo
$17,499 — —
AYVAKIT
$11,687 — —
NUCALA
$6,471 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

1,410 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record